Stay updated on Nivolumab Post Induction in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Post Induction in NSCLC Clinical Trial page.
Latest updates to the Nivolumab Post Induction in NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new Locations section with the Gyeonggi-do site was added to the study page to indicate recruitment locations. The previous Gyeonggi-do Locations label was removed and the HHS Vulnerability Disclosure link was removed; the page revision updated to v3.3.3.SummaryDifference0.2%
- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedRevision: v3.3.2 is shown on the page, replacing v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check54 days agoChange DetectedRemoved the temporary government funding/status notice from the page; the study details remain unchanged.SummaryDifference0.4%
- Check68 days agoChange DetectedNo additions or deletions detected for the page. The content and layout remain unchanged.SummaryDifference0.5%
- Check97 days agoChange DetectedUpdated operating-status notice and version to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%
- Check104 days agoChange DetectedUpdated contact details and updated revision to v3.1.0; removed old revision v3.0.2.SummaryDifference0.1%
Stay in the know with updates to Nivolumab Post Induction in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Post Induction in NSCLC Clinical Trial page.